DrugMapper


Trade Names:	CEFTRIAXONE CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER CEFTRIAXONE IN PLASTIC CONTAINER CEFTRIAXONE SODIUM ROCEPHIN ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER
Synonyms:	Cefraden Ceftriaxone Ceftriaxone (as sodium) Ceftriaxone disodium salt Ceftriaxone disodium salt hemiheptahydrate Ceftriaxone sodium Ceftriaxone sodium anhydrous Ceftriaxone sodium hydrate Ceftriaxone sodium sesquaterhydrate Megion RO 13-9904 RO-13-9904 Rocefin Rocephin Sodium ceftriaxone, anhydrous
Status:	Approved (1984)
Entry Type:	Small molecule
Molecule Category:	Salt
UNII:	023Z5BR09K
Parent Compound:	CEFTRIAXONE


InChI Key	YOBPSXOHCHDCMU-VKZZUTNHSA-M
Smile	CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1.[Na+]
InChI	InChI=1S/C18H18N8O7S3.Na/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7;/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32);/q;+1/p-1/b24-8-;/t9-,15-;/m1./s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C18H22N8Na2O10S3
Molecular Weight	652.6
AlogP	-1.2
Hydrogen Bond Acceptor	15.0
Hydrogen Bond Donor	4.0
Number of Rotational Bond	8.0
Polar Surface Area	215.22
Molecular species	ACID
Aromatic Rings	2.0
Heavy Atoms	36.0

Action	Mechanism of Action	Reference
INHIBITOR	Bacterial penicillin-binding protein inhibitor	PubMed DailyMed Wikipedia

Mesh Heading	Maximum Phase	Mesh ID	Reference
Urinary Tract Infections	4	D014552	ClinicalTrials
Neoplasms	1	D009369	ClinicalTrials

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Parent

Mixture

Side Effects from Label

Side Effects (PT)

Side effects	Relative Frequency (%)	Labels
General disorders and administration site conditions Pain	9.4
Blood and lymphatic system disorders Eosinophilia	6.0
Blood and lymphatic system disorders Thrombocytosis	5.1
Blood and lymphatic system disorders Eosinophilia	4.6
Gastrointestinal disorders Diarrhoea	3.3
Gastrointestinal disorders Diarrhoea	2.7
Blood and lymphatic system disorders Leukopenia	2.1
Blood and lymphatic system disorders Leukopenia	2.0
Skin and subcutaneous tissue disorders Dermatitis	1.7
Skin and subcutaneous tissue disorders Rash	1.7
Skin and subcutaneous tissue disorders Dermatitis	1.3
Skin and subcutaneous tissue disorders Rash	1.3
Hepatobiliary disorders Cholelithiasis	0.1
Respiratory, thoracic and mediastinal disorders Epistaxis	0.1
Renal and urinary disorders Glycosuria	0.1
Nervous system disorders Paraesthesia	0.1
Investigations Prothrombin time shortened	0.1
Immune system disorders Serum sickness	0.1
Gastrointestinal disorders Stomatitis	0.1
Vascular disorders Thrombophlebitis	0.1

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
General disorders and administration site conditions	10.87
Skin and subcutaneous tissue disorders	10.06
Immune system disorders	8.57
Vascular disorders	7.13
Respiratory, thoracic and mediastinal disorders	7.1
Nervous system disorders	6.55
Gastrointestinal disorders	5.78
Injury, poisoning and procedural complications	5.35
Hepatobiliary disorders	4.84
Infections and infestations	4.78
Cardiac disorders	4.71
Investigations	4.7
Blood and lymphatic system disorders	4.31
Renal and urinary disorders	4.12
Metabolism and nutrition disorders	2.59
Musculoskeletal and connective tissue disorders	2.57
Psychiatric disorders	2.52

Resources	Reference
ChEMBL	CHEMBL3183968
EPA CompTox	DTXSID5045887
FDA SRS	023Z5BR09K
PubChem	71307090

CEFTRIAXONE SODIUM

Structure

Physicochemical Descriptors

Pharmacology

Indications

Related Entries

Scaffolds

Side Effects from Label

Adverse Reactions

Cross References


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70